Cargando…
Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
Up to 25% of patients with profound neutropenia lasting for >10 days develop lung infiltrates, which frequently do not respond to broad-spectrum antibacterial therapy. While a causative pathogen remains undetected in the majority of cases, Aspergillus spp., Pneumocystis jirovecii, multi-resistant...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
THE AUTHORS. Published by Elsevier Ltd.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269340/ https://www.ncbi.nlm.nih.gov/pubmed/24833776 http://dx.doi.org/10.1093/annonc/mdu192 |
_version_ | 1782349346776285184 |
---|---|
author | Maschmeyer, G. Carratalà, J. Buchheidt, D. Hamprecht, A. Heussel, C.P. Kahl, C. Lorenz, J. Neumann, S. Rieger, C. Ruhnke, M. Salwender, H. Schmidt-Hieber, M. Azoulay, E. |
author_facet | Maschmeyer, G. Carratalà, J. Buchheidt, D. Hamprecht, A. Heussel, C.P. Kahl, C. Lorenz, J. Neumann, S. Rieger, C. Ruhnke, M. Salwender, H. Schmidt-Hieber, M. Azoulay, E. |
author_sort | Maschmeyer, G. |
collection | PubMed |
description | Up to 25% of patients with profound neutropenia lasting for >10 days develop lung infiltrates, which frequently do not respond to broad-spectrum antibacterial therapy. While a causative pathogen remains undetected in the majority of cases, Aspergillus spp., Pneumocystis jirovecii, multi-resistant Gram-negative pathogens, mycobacteria or respiratory viruses may be involved. In at-risk patients who have received trimethoprim–sulfamethoxazole (TMP/SMX) prophylaxis, filamentous fungal pathogens appear to be predominant, yet commonly not proven at the time of treatment initiation. Pathogens isolated from blood cultures, bronchoalveolar lavage (BAL) or respiratory secretions are not always relevant for the etiology of pulmonary infiltrates and should therefore be interpreted critically. Laboratory tests for detecting Aspergillus galactomannan, β-d-glucan or DNA from blood, BAL or tissue samples may facilitate the diagnosis; however, most polymerase chain reaction assays are not yet standardized and validated. Apart from infectious agents, pulmonary side-effects from cytotoxic drugs, radiotherapy or pulmonary involvement by the underlying malignancy should be included into differential diagnosis and eventually be clarified by invasive diagnostic procedures. Pre-emptive treatment with mold-active systemic antifungal agents improves clinical outcome, while other microorganisms are preferably treated only when microbiologically documented. High-dose TMP/SMX is first choice for treatment of Pneumocystis pneumonia, while cytomegalovirus pneumonia is treated primarily with ganciclovir or foscarnet in most patients. In a considerable number of patients, clinical outcome may be favorable despite respiratory failure, so that intensive care should be unrestrictedly provided in patients whose prognosis is not desperate due to other reasons. |
format | Online Article Text |
id | pubmed-4269340 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | THE AUTHORS. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-42693402015-03-24 Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) Maschmeyer, G. Carratalà, J. Buchheidt, D. Hamprecht, A. Heussel, C.P. Kahl, C. Lorenz, J. Neumann, S. Rieger, C. Ruhnke, M. Salwender, H. Schmidt-Hieber, M. Azoulay, E. Ann Oncol Article Up to 25% of patients with profound neutropenia lasting for >10 days develop lung infiltrates, which frequently do not respond to broad-spectrum antibacterial therapy. While a causative pathogen remains undetected in the majority of cases, Aspergillus spp., Pneumocystis jirovecii, multi-resistant Gram-negative pathogens, mycobacteria or respiratory viruses may be involved. In at-risk patients who have received trimethoprim–sulfamethoxazole (TMP/SMX) prophylaxis, filamentous fungal pathogens appear to be predominant, yet commonly not proven at the time of treatment initiation. Pathogens isolated from blood cultures, bronchoalveolar lavage (BAL) or respiratory secretions are not always relevant for the etiology of pulmonary infiltrates and should therefore be interpreted critically. Laboratory tests for detecting Aspergillus galactomannan, β-d-glucan or DNA from blood, BAL or tissue samples may facilitate the diagnosis; however, most polymerase chain reaction assays are not yet standardized and validated. Apart from infectious agents, pulmonary side-effects from cytotoxic drugs, radiotherapy or pulmonary involvement by the underlying malignancy should be included into differential diagnosis and eventually be clarified by invasive diagnostic procedures. Pre-emptive treatment with mold-active systemic antifungal agents improves clinical outcome, while other microorganisms are preferably treated only when microbiologically documented. High-dose TMP/SMX is first choice for treatment of Pneumocystis pneumonia, while cytomegalovirus pneumonia is treated primarily with ganciclovir or foscarnet in most patients. In a considerable number of patients, clinical outcome may be favorable despite respiratory failure, so that intensive care should be unrestrictedly provided in patients whose prognosis is not desperate due to other reasons. THE AUTHORS. Published by Elsevier Ltd. 2015-01 2020-01-06 /pmc/articles/PMC4269340/ /pubmed/24833776 http://dx.doi.org/10.1093/annonc/mdu192 Text en © 2015 THE AUTHORS Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Maschmeyer, G. Carratalà, J. Buchheidt, D. Hamprecht, A. Heussel, C.P. Kahl, C. Lorenz, J. Neumann, S. Rieger, C. Ruhnke, M. Salwender, H. Schmidt-Hieber, M. Azoulay, E. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) |
title | Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) |
title_full | Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) |
title_fullStr | Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) |
title_full_unstemmed | Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) |
title_short | Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) |
title_sort | diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic sct excluded): updated guidelines of the infectious diseases working party (agiho) of the german society of hematology and medical oncology (dgho) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269340/ https://www.ncbi.nlm.nih.gov/pubmed/24833776 http://dx.doi.org/10.1093/annonc/mdu192 |
work_keys_str_mv | AT maschmeyerg diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho AT carratalaj diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho AT buchheidtd diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho AT hamprechta diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho AT heusselcp diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho AT kahlc diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho AT lorenzj diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho AT neumanns diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho AT riegerc diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho AT ruhnkem diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho AT salwenderh diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho AT schmidthieberm diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho AT azoulaye diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho |